In-licensor's lament

OXFORD - Despite shrugs from the market, Vanguard Medica Group plc believes that its submission of a U.S. NDA for its Miguard frovatriptan migraine treatment is a testament to the company's virtually integrated business model.

CEO Robert Mansfield told BioCentury that the company completed the development of frovatriptan in four and a quarter years compared with the industry norm of six years through the same stages. He anticipates adding to last week's FDA filing with a European application in the near future.

see Ebb & Flow, A16), market reaction to the NDA news was muted. VGD gained 3.5p (2 percent) to 163.5p. In the past year, the

Read the full 1053 word article

How to gain access

Continue reading with a
two-week free trial.